Episodes

In this episode, Dr. F. Anthony Greco, medical oncologist at Tennessee Oncology, discusses the role that precision medicine has played in improving our diagnosis and treatment of cancer.

In this episode, Dr. F. Anthony Greco, medical oncologist at Tennessee Oncology, discusses the role that precision medicine has played in improving our diagnosis and treatment of cancer.

In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx. Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for geneti...

In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx. Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for geneti...

In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx. Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for geneti...

Christopher Boone, Vice President and Global Head of Health Economics & Outcomes Research at AbbVie, shares his thoughts on how using data to understand a patient’s real-world environment can expand the practice of Precision Medicine.

Christopher Boone, Vice President and Global Head of Health Economics & Outcomes Research at AbbVie, shares his thoughts on how using data to understand a patient’s real-world environment can expand the practice of Precision Medicine.

Christopher Boone, Vice President and Global Head of Health Economics & Outcomes Research at AbbVie, shares his thoughts on how using data to understand a patient’s real-world environment can expand the practice of Precision Medicine.

It is fitting that our first guests on Season 3 of the Precision Medicine Podcast are Rob Metcalf, CEO of Concert Genetics and Clynt Taylor, CEO of Trapelo Health who are both innovators in precision medicine technology. What we learn from them in this episode is that after 20 years of hearing about the “promise of precision medicine,” technology has reached a critical point where it can begin to accelerate that progress. Read the full summary, listen and learn more here.

It is fitting that our first guests on Season 3 of the Precision Medicine Podcast are Rob Metcalf, CEO of Concert Genetics and Clynt Taylor, CEO of Trapelo Health who are both innovators in precision medicine technology. What we learn from them in this episode is that after 20 years of hearing about the “promise of precision medicine,” technology has reached a critical point where it can begin to accelerate that progress. Read the full summary, listen and learn more here.

It is fitting that our first guests on Season 3 of the Precision Medicine Podcast are Rob Metcalf, CEO of Concert Genetics and Clynt Taylor, CEO of Trapelo Health who are both innovators in precision medicine technology. What we learn from them in this episode is that after 20 years of hearing about the “promise of precision medicine,” technology has reached a critical point where it can begin to accelerate that progress. Read the full summary, listen and learn more here.

In this episode, and in honor of lung cancer awareness month we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of Hematology Oncology at Memorial Cancer Institute who focuses on treating lung cancer. Hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he sees COVID-19 impacting the treatment of cancer. Tune in to the full episode here.

In this episode, and in honor of lung cancer awareness month we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of Hematology Oncology at Memorial Cancer Institute who focuses on treating lung cancer. Hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he sees COVID-19 impacting the treatment of cancer. Tune in to the full episode here.

In this episode, and in honor of lung cancer awareness month we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of Hematology Oncology at Memorial Cancer Institute who focuses on treating lung cancer. Hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he sees COVID-19 impacting the treatment of cancer. Tune in to the full episode here.

In the first of a two-part podcast, Gabriel A. Bien-Willner MD, PhD, FCAP, Medical Director at MolDX, and Chief Medical Officer at Palmetto GBA shares how he has helped implement payer controls and coverage and set policies for affiliated Medicare Administrative Contractors in 28 states. In the past, payers have had to navigate the growing field of precision medicine without the benefit of expertise, so their only guidance came from the NCCN or consultations with other experts in the field. Tod...

In the first of a two-part podcast, Gabriel A. Bien-Willner MD, PhD, FCAP, Medical Director at MolDX, and Chief Medical Officer at Palmetto GBA shares how he has helped implement payer controls and coverage and set policies for affiliated Medicare Administrative Contractors in 28 states. In the past, payers have had to navigate the growing field of precision medicine without the benefit of expertise, so their only guidance came from the NCCN or consultations with other experts in the field. Tod...

In the first of a two-part podcast, Gabriel A. Bien-Willner MD, PhD, FCAP, Medical Director at MolDX, and Chief Medical Officer at Palmetto GBA shares how he has helped implement payer controls and coverage and set policies for affiliated Medicare Administrative Contractors in 28 states. In the past, payers have had to navigate the growing field of precision medicine without the benefit of expertise, so their only guidance came from the NCCN or consultations with other experts in the field. Tod...

Dr. Mark Moasser, a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials. At Trapelo, connecting oncologists with patient-appropriate clinical trials is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the ful...

Dr. Mark Moasser, a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials. At Trapelo, connecting oncologists with patient-appropriate clinical trials is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the ful...

Dr. Mark Moasser, a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials. At Trapelo, connecting oncologists with patient-appropriate clinical trials is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the ful...

In this episode, Clynt Taylor, CEO at Trapelo Health, talks with Lori Brisbin, Vice President of Precision Medicine at Texas Oncology, one of the largest practices in the United States. The discussion centers on how this expansive network of oncologists is leveraging the web-based Trapelo™ platform to provide evidence-based decision support to its physicians and bring precision medicine to the forefront of patient care

In this episode, Clynt Taylor, CEO at Trapelo Health, talks with Lori Brisbin, Vice President of Precision Medicine at Texas Oncology, one of the largest practices in the United States. The discussion centers on how this expansive network of oncologists is leveraging the web-based Trapelo™ platform to provide evidence-based decision support to its physicians and bring precision medicine to the forefront of patient care

In this episode, Clynt Taylor, CEO at Trapelo Health, talks with Lori Brisbin, Vice President of Precision Medicine at Texas Oncology, one of the largest practices in the United States. The discussion centers on how this expansive network of oncologists is leveraging the web-based Trapelo™ platform to provide evidence-based decision support to its physicians and bring precision medicine to the forefront of patient care

On this Precision Medicine Podcast, author and CEO of the Toft Group (a ZRG company), Robin Toft, joins us to discuss her new book, We Can, and share her thoughts on the need for more women and greater diversity in the C-suite and the boardroom within the life science industry. Read the full summary here.